Marrow suppression and /or cytopenia Steroid induced side effects or OR Significant toxicity. Corticosteroid therapy is contraindicated or has resulted in unacceptable side effects or significant toxicity AND Unresponsive to at least two immunosuppressant agents OR Immunosuppressant medication is contraindicated or has resulted in unacceptable side effects or significant toxicity Review Review by a specialist in collaboration with an Review criteria drafted following consultation with Criteria Ophthalmologist is required within 3 months of RANZCO and confirm a treatment period of three months treatment to determine whether the patient has prior to assessing initial clinical response. Since responded, and annually thereafter. ophthalmologists rarely prescribe intravenous immunoglobulins, they have indicated support for Documentation of clinical effectiveness is necessary for collaborative care with another specialist in all cases. They continuation of IVIg therapy. recommend that the treating ophthalmologist consults the On review of the initial authorisation period collaborating specialist with regard to dosing with the treating ophthalmologist providing assessments of disease Clinical effectiveness of Ig therapy can be demonstrated activity, severity and progression. by:
OR Corticosteroid therapy is contraindicated or has resulted in unacceptable side effects or significant toxicity AND Unresponsive to at least two immunosuppressant agents OR Immunosuppressant medication is contraindicated or has resulted in unacceptable side effects or significant toxicity Marrow suppression and /or cytopenia Steroid induced side effects or Significant toxicity. Review Criteria Review by a specialist in collaboration with an Ophthalmologist is required within 3 months of treatment to determine whether the patient has responded, and annually thereafter. Documentation of clinical effectiveness is necessary for continuation of IVIg therapy. On review of the initial authorisation period Clinical effectiveness of Ig therapy can be demonstrated by: Review criteria drafted following consultation with RANZCO and confirm a treatment period of three months prior to assessing initial clinical response. Since ophthalmologists rarely prescribe intravenous immunoglobulins, they have indicated support for collaborative care with another specialist in all cases. They recommend that the treating ophthalmologist consults the collaborating specialist with regard to dosing with the treating ophthalmologist providing assessments of disease activity, severity and progression.
Immunology-Ch7-Autoimmune-retinopathy-%28previously-Autoimmune-uveitis%29.DOCX